BACKGROUND:Renal stones in anomalous kidneys pose surgical challenges due to altered anatomy. Miniaturized percutaneous nephrolithotomy (mini-PCNL) reduces morbidity, but concerns remain about stone-free rates (SFRs) and infection. Suction-assisted mini-PCNL (SM-PCNL) enhances fragment removal and controls intrarenal pressure, but its role in anomalous kidneys is unclear. OBJECTIVE:To evaluate perioperative outcomes of SM-PCNL in anomalous kidneys in a multicenter, real-world study and assess variations based on positioning, lithotripsy modality, and renal anomalies. METHODOLOGY:This prospective study across 15 centers (January-December 2024) included 287 adults undergoing SM-PCNL for renal stones in anomalous kidneys. Patients with normal anatomy, non-suction PCNL, or incomplete data were excluded. SFR was assessed via a 30-day non-contrast CT: 100% stone-free (Grade A), residual fragments ≤4 mm (Grade B), or >4 mm/multiple (Grade C, requiring reintervention). RESULTS:Malrotation (65.5%) was the most common anomaly, followed by duplex systems (25.1%), horseshoe kidneys (8.4%), and ectopic kidneys (1.0%). Median stone size was 1.7 cm. Supine positioning was used in 54.4%. Lithotripsy was performed with holmium laser (50.9%), thulium fiber laser (11.1%), or pneumatic lithotripsy (26.1%). Intraoperative clearance was 95.4%. At 30 days, 93.4% achieved Grade A, 5.6% Grade B, and 1.0% required reintervention. Complications were low; 0.7% had sepsis requiring intensive care unit admission. No transfusions or pleural injuries occurred. CONCLUSION:SM-PCNL using 18F suction sheaths with laser in a single stage achieved 93.4% complete SFR with negligible complications and minimal reintervention.
This review synthesizes current literature on the epidemiology, mechanistic links, and clinical consequences of the COPD-CKD association. In addition to evaluating established risk factors such as age and tobacco smoking, we discuss emerging insights into the roles of novel biomarkers and epigenetic modifications in bridging the lung-kidney axis. The review further examines how the presence of CKD influences clinical management in COPD patients, including impacts on drug dosing, electrolyte balance, acid-base homeostasis, and outcomes during acute exacerbations, and conversely, how COPD can adversely affect renal function. Recognizing that the dual burden of COPD and CKD may worsen patient prognosis by increasing the risk for cardiovascular events, hospitalizations, and mortality, we advocate for early detection, routine screening using both creatinine and cystatin C measurements, and a multidisciplinary approach to care. Finally, we outline future research directions aimed at standardizing screening protocols, refining risk stratification, and developing targeted therapies that address shared pathogenic pathways.
The treatment landscape for Chronic Lymphocytic Leukemia has rapidly evolved from chemoimmunotherapy to highly effective targeted agents. Despite superior efficacy and safety profiles of these novel agents, challenges persist, particularly due to limited head-to-head trials and regional differences in drug availability and molecular testing. This multiregional expert consensus, developed by 13 hematology experts from Latin America, the Middle East and Africa, Asia-Pacific, and Russia using an adapted Delphi approach, provides evidence-informed recommendations for first-line treatment and sequencing tailored to patient risk and real-world resource constraints. The panel agreed on 16 key statements, emphasizing that targeted therapies are preferred for nearly all newly diagnosed patients. Molecular testing for del(17p), TP53 mutation, and IGHV status is recommended for prognosis and treatment planning. High-risk patients (del(17p) and/or TP53 mutation) should preferably receive continuous therapy with second-generation BTK inhibitors (acalabrutinib or zanubrutinib), which are generally preferred over ibrutinib due to safety advantages. Low-risk patients (IGHV-mutated, without del(17p)/TP53) are best suited for time-limited, venetoclax-based regimens. Upon relapse, switching therapeutic classes is recommended: venetoclax after continuous BTKi therapy, and BTKi after fixed-duration venetoclax. Overall, the consensus underscores the importance of individualized, shared decision-making that accounts for molecular risk, comorbidities, and patient preferences, while highlighting global disparities in access to modern CLL therapies.
The paper is focused on a shift in approaches to treatment of heart failure (HF) and chronic kidney disease (CKD) as components of cardiovascularkidneymetabolic ( CKM) syndrome. It reviews evolution of concepts regarding the pathogenesis of heart failure with preserved ejection fraction (HFpEF) and, consequently, changing views on the role of reninangiotensin system activation in the development of this HF type. Current epidemiological data demonstrating a substantial increase in HFpEF prevalence are presented. The current classification of CKM syndrome which provides the basis for selecting background therapy at each stage of the syndrome, is described. The key role of abnormal adipose tissue in HFpEF development, as well as its important contribution to development and progression of CKD, is discussed. Significance of the bidirectional relationship between HF and CKD causing progression of both diseases is being discussed. A shift in approaches to background therapy for CKD and a place of irbesartan in the current management of patients with CKM syndrome and impaired kidney function are on the carpet. Data on the potential modification of treatment response in overweight and obese patients are presented. The findings of the I PRESERVE trial assessing irbesartan effects in patients with HFpEF, as well as the results of two pivotal irbesartan trials in patients with type 2 diabetes at high risk of CKD onset or progression, are discussed in a modern light. Data on the role of PPARγ activation in a beneficial effect of irbesartan on metabolic parameters, as well as its effects on uric acid levels in patients with hyperuricemia, are presented. KEYWORDS: cardiovascularkidneymetabolic syndrome, heart failure, chronic kidney disease, irbesartan. FOR CITATION: Gilyarevsky S.R., Akhmetova K.R., Golschmidt M.V., Shchedrina A.Yu. Heart failure and chronic kidney disease in the structure of cardiovascular-kidney-metabolic syndrome: a shift in paradigm and treatment approaches. Russian Medical Inquiry. 2026;10(9):621–628 (in Russ.). DOI: 10.32364/2587-6821-2026-10-9-5